DSpace JSPUI
DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets
Learn More
Browsing by Author Diaz, R.
Showing results 1 to 5 of 5
Issue Date | Title | Author(s) |
2024 | Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study | Bittner, V. A.; Schwartz, G.G.; Bhatt, D.L.; Chua, T; de Silva, H.A.; Diaz, R.; Goodman, S.G.; Harrington, R.A.; Jukema, J.W.; McGinniss, J.; Pordy, R.; Garon, G.; Scemama, M.; White, H.D.; Steg, P.G.; Szarek, M.; ODYSSEY OUTCOMES Investigators |
2024 | Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after aute coronary syndrome: Odyssey outcomes. | Bittner, V.A.; Schwartz, G.G.; Bhatt, D.L.; Chua, T.; De Silva, H.A.; Diaz, R.; Goodman, S.G.; Harrington, R.A.; Jukema, J.W.; Mcginniss, J.; Pordy, R.; Garon, G.; Scemama, M.; White, H.D.; Steg, G.; Szarek, M. |
2019 | Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial. | Jukema, J.W.; Szarek, M.; Zijlstra, L.E.; de Silva, H.A.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, H. A.; Karpov, Y.; Moryusef, A.; Pordy, R.; Prieto, J.C.; Roe, M.T.; White, H.D.; Zeiher, A. M.; Schwartz, G. G.; Steg, P.G.; ODYSSEY OUTCOMES Committees and Investigators |
2019 | Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. | Ray, K.K.; Colhoun, H.M.; Szarek, M.; Baccara-Dinet, M.; Bhatt, D.L.; Bittner, V.A.; Budaj, A.J.; Diaz, R.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Jukema, J.W.; Loizeau, V.; Lopes, R.D.; Moryusef, A.; Murin, J.; Pordy, R.; Ristic, A.D.; Roe, M.T.; Tuñón, J.; White, H.D.; Zeiher, A.M.; Schwartz, G.G.; Steg, P.G.; de Silva, H.A.ODYSSEY OUTCOMES Committees and Investigators. |
2021 | Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol | Schwartz, G.G.; Szarek, M.; Bittner, V.A.; Diaz, R.; Goodman, S.G.; Jukema, J.W.; Landmesser, U.; López-Jaramillo, P.; Manvelian, G.; Pordy, R.; Scemama, M.; Sinnaeve, P.R.; White, H.D.; Steg, Ph.G.; ODYSSEY Outcomes Committees and Investigators |